Results 191 to 200 of about 23,609 (230)

Model-Assisted Spleen Contouring for Assessing Splenomegaly in Myelofibrosis: A Fast and Reproducible Approach to Evaluate Progression and Treatment Response. [PDF]

J Clin Med
Sharbatdaran A, Cohen T, Dev H, Sattar U, Bazojoo V, Wang Y, Hu Z, Zhu C, He X, Romano D, Scandura JM, Prince MR.   +11 more
europepmc   +1 more source

Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates. [PDF]

Blood Cancer J
Dingli S, Fathima S, Faldu P, Gangat N, Dingli D, Tefferi A.   +5 more
europepmc   +1 more source

Primary myelofibrosis progression: a game of cellular telephone. [PDF]

Haematologica
Wadley L, Fleischman A.
europepmc   +1 more source

Assessing the contribution of myelofibrosis to a leukoerythroblastic blood picture. [PDF]

Hematol Transfus Cell Ther
Langabeer SE.
europepmc   +1 more source

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. [PDF]

Nat Commun
Maslah N, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, Verger E, De Oliveira RD, Culeux C, Mlayah B, Gauthier N, Gonzales F, Zhao LP, Ganesan S, Gou P, Ling F, Soret-Dulphy J, Parquet N, Vainchenker W, Raffoux E, Padua RA, Giraudier S, Marty C, Plo I, Lobry C, Stegmaier K, Puissant A, Kiladjian JJ, Cassinat B, Benajiba L.   +29 more
europepmc   +1 more source

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

MARCHETTI M, Vannucchi A, Mascarenhas J, Alvarez-Larran A, Bose P, Gale R, Harrison C, Hehlmann R, Kiladjian J, Koschmieder S, Mesa R, Passamonti F, Rambaldi A, Tefferi A, Barbui T.   +14 more
europepmc   +1 more source

Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary. [PDF]

Future Oncol
Harrison C, Kiladjian JJ, Vannucchi AM, Mesa RA.   +3 more
europepmc   +1 more source

Treatment of <i>JAK2</i> V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report. [PDF]

Ann Med Surg (Lond)
Zhu F, Wang H, Qiu L.
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. [PDF]

Future Oncol
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, SENTRY investigators.   +10 more
europepmc   +1 more source